trans-3-hexenoyl comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
== Education == Kowalska received a master's degree in chemistry in 1968 and a PhD in physical chemistry in 1972, both from Higher Pedagogical School in Katowice, which became University of Silesia in Katowice. She conducted post-doctoral research at University of Salford in the UK, under the supervision of Hans Suschitzky. She received a habilitation degree in 1988 from Maria Curie-Skłodowska University, with the habilitation dissertation titled A New Thermodynamic Model of the Chromatographic Process and its Applications.
Combating Terrorism Center: 20–23. Hitti, Philip K. (1966). The Origins of the Druze People: With Extracts from Their Sacred Writings. AMS Press. Kratschkowsky, I. & Halm, Heinz (1993). "al-Muḳtanā". In Bosworth, C. E.; van Donzel, E.; Heinrichs, W. P. & Pellat, Ch. (eds.). The Encyclopaedia of Islam, Second Edition. Volume VII: Mif–Naz. Leiden: E. J. Brill. p. 544. doi:10.1163/1573-3912_islam_SIM_5483. ISBN 978-90-04-09419-2. Van Leeuwen, Richard (1994). Notables and Clergy in Mount Lebanon: The Khāzin Sheikhs and the Maronite Church, 1736–1840. BRILL. ISBN 978-90-04-09978-4. Levi Della Vida, G. (2000). "Taym Allah". In Bearman, P. J.; Bianquis, Th.; Bosworth, C. E.; van Donzel, E. & Heinrichs, W. P. (eds.). The Encyclopaedia of Islam, Second Edition. Volume X: T–U. Leiden: E. J. Brill. pp. 400–401. ISBN 978-90-04-11211-7. Makarim, Sami Nasib (1974). The Druze Faith. Caravan Books. ISBN 978-0-88206-003-3. McGrath, Alister E. (2006). Christianity: An Introduction. John Wiley & Sons. pp. 4–6. ISBN 978-1-4051-0899-7. Archived from the original on September 10, 2015. Retrieved August 14, 2015. Mishaqa, Mikhail (1988). Thackston, Wheeler McIntosh (ed.). Murder, Mayhem, Pillage, and Plunder: The History of the Lebanon in the 18th and 19th Centuries by Mikhayil Mishaqa (1800-1873). State University of New York Press. ISBN 978-0-88706-712-9. Morgenstern, Julian (1966). The Rites of Birth, Marriage, Death, and Kindred Occasions Among the Semites. Hebrew Union College Press. Olsaretti, Alessandro (December 2008). "Political Dynamics in the Rise of Fakhr al-Din, 1590-1633".
Under the theory that federal law, passed pursuant to Constitutional authority, overrules conflicting state laws, federal authorities still claim the authority to seize, arrest, and prosecute for possession and sales of these substances, even in states where they are legal under state law. The first wave was the legalization by 27 states of laetrile in the late 1970s. This drug was used as a treatment for cancer, but scientific studies both before and after this legislative trend found it ineffective. The second wave concerned medical marijuana in the 1990s and 2000s. Though Virginia passed legislation allowing doctors to recommend cannabis for glaucoma or the side effects of chemotherapy, a more widespread trend began in California with the Compassionate Use Act of 1996. When the FDA requested Endo Pharmaceuticals on June 8, 2017, to remove an extended-release formulation of oxymorphone hydrochloride from the market, it was the first request in FDA history to recall an effective drug over its potential for misuse. In February 2025, FDA food division head Jim Jones quit in protest of the "indiscriminate" layoffs of 89 staff members by the Donald Trump administration. In May 2025, the FDA announced changes in its COVID-19 vaccine policy, intending to limit approved indications use for adults over 65 and individuals at higher risk of complications in the fall. For healthy Americans younger than 65, the agency indicated it would likely require additional clinical trials with placebo controls to demonstrate benefit before approving wider access.
On June 28, 2007, a team at the J. Craig Venter Institute published an article in Science Express, saying that they had successfully transplanted the natural DNA from a Mycoplasma mycoides bacterium into a Mycoplasma capricolum cell, creating a bacterium which behaved like a M. mycoides. On Oct 6, 2007, Craig Venter announced in an interview with UK's The Guardian newspaper that the same team had synthesized a modified version of the single chromosome of Mycoplasma genitalium artificially. The chromosome was modified to eliminate all genes which tests in live bacteria had shown to be unnecessary. The next planned step in this minimal genome project is to transplant the synthesized minimal genome into a bacterial cell with its old DNA removed; the resulting bacterium will be called Mycoplasma laboratorium. The next day the Canadian bioethics group, ETC Group issued a statement through their representative, Pat Mooney, saying Venter's "creation" was "a chassis on which you could build almost anything". The synthesized genome had not yet been transplanted into a working cell. On May 21, 2010, Science reported that the Venter group had successfully synthesized the genome of the bacterium Mycoplasma mycoides from a computer record, and transplanted the synthesized genome into the existing cell of a Mycoplasma capricolum bacterium that had its DNA removed. The "synthetic" bacterium was viable, i.e. capable of replicating billions of times. The team had originally planned to use the M. genitalium bacterium they had previously been working with, but switched to M.
Sources: en.wikipedia.org
After menopause, the body produces less estrogen. This causes atrophic vaginitis (thinning and inflammation of the vaginal walls), which can lead to vaginal itching, burning, bleeding, soreness, or vaginal dryness (a decrease in lubrication). Vaginal dryness can cause discomfort on its own or discomfort or pain during sexual intercourse. Hot flashes are also characteristic of menopause. Menopause also affects the composition of vaginal support structures. The vascular structures become fewer with advancing age. Specific collagens become altered in composition and ratios. It is thought that the weakening of the support structures of the vagina is due to the physiological changes in this connective tissue. Menopausal symptoms can be eased by estrogen-containing vaginal creams, non-prescription, non-hormonal medications, vaginal estrogen rings such as the Femring, or other hormone replacement therapies, but there are risks (including adverse effects) associated with hormone replacement therapy. Vaginal creams and vaginal estrogen rings may not have the same risks as other hormone replacement treatments. Hormone replacement therapy can treat vaginal dryness, but a personal lubricant may be used to temporarily remedy vaginal dryness specifically for sexual intercourse. Some women have an increase in sexual desire following menopause. It may be that menopausal women who continue to engage in sexual activity regularly experience vaginal lubrication similar to levels in women who have not entered menopause, and can enjoy sexual intercourse fully.
== Further reading == Inglis, Julia J.; Criado, Gabriel; Medghalchi, Mino; Andrews, Melanie; Sandison, Ann; Feldmann, Marc; Williams, Richard O. (29 October 2007). "Collagen-induced arthritis in C57BL/6 mice is associated with a robust and sustained T-cell response to type II collagen". Arthritis Research & Therapy. 9 (5): R113. doi:10.1186/ar2319. ISSN 1478-6354. PMC 2212575. PMID 17967186. Pietrosimone, K. M.; Jin, M.; Poston, B.; Liu, P. (20 October 2015). "Collagen-Induced Arthritis: A model for Murine Autoimmune Arthritis". Bio-Protocol. 5 (20) e1626. doi:10.21769/bioprotoc.1626. ISSN 2331-8325. PMC 4629450. PMID 26539560. Holmdahl, Rikard; Bockermann, Robert; Bäcklund, Johan; Yamada, Hisakata (1 February 2002). "The molecular pathogenesis of collagen-induced arthritis in mice—a model for rheumatoid arthritis". Ageing Research Reviews. 1 (1): 135–147. doi:10.1016/S0047-6374(01)00371-2. ISSN 1568-1637. PMID 12039453. S2CID 28243127.
=== Scarless wound healing === Scarless wound healing is a concept based on the healing or repair of the skin (or other tissue/organs) after injury with the aim of healing with subjectively and relatively less scar tissue than normally expected. Scarless healing is sometimes mixed up with the concept of scar free healing, which is wound healing that results in absolutely no scar (free of scarring) may occur naturally at some locations of the human body and research in 2025 has decoded molecular players that drive that scarless healing. However, they are different concepts. The opposite of scarless wound healing is scarification (wound healing to scar more). Historically, certain cultures consider scarification attractive; however, this is generally not the case in the modern western society, in which many patients are turning to plastic surgery clinics with unrealistic expectations. Depending on scar type, treatment may be invasive (intralesional steroid injections, surgery) and/or conservative (compression therapy, topical silicone gel, brachytherapy, photodynamic therapy). Clinical judgment is necessary to successfully balance the potential benefits of the various treatments available against the likelihood of a poor response and possible complications resulting from these treatments. Many of these treatments may only have a placebo effect, and the evidence base for the use of many current treatments is poor.
== Immunoglobulin-like receptors == Glycoprotein VI Receptor GPVI belongs to immunoglobulin family of glycoproteins. It consists of two extramembrane immunoglobulin domains, which are associated with extracellular glycosylated mucine and together they form a stalk. Another part of the receptor consists of transmembrane helix with a short cytosolic domain. A FcRγ chain with ITAM (immunoreceptor tyrosine-based activation motif) domain is associated with the transmembrane domain. The short cytosolic domain interacts with calmodulin and Src kinases Lyn and Fyn. These Src kinases phosphorylate tyrosine in ITAM domain and activate a signalling cascade. Glycoprotein VI belongs to collagen receptors that are primarily expressed on platelets surface. Together with integrin receptor α2β1 they provide coagulation cascade activation when a blood-vessel is damaged. When damage occurs, endothelial collagen is uncovered and is bound by GPVI receptor on platelets. This interaction activates signalling cascades leading to coagulation factors release. Mainly fibrillar collagens type I and III serve as ligands. Functions include: Platelet adhesion and activation - the most important platelet collagen receptor in terms of signaling. LAIR1(Leukocyte-associated IG-like receptor) works as inhibition signal for different immune cells. Lair-1 consists of Ig domain, transmembrane helix and a short cytosolic domain, which includes two inhibition motifs (ITIMs), which can block tyrosine domain when activated.
Curium is one of the most radioactive isolable elements. Its two most common isotopes 242Cm and 244Cm are strong alpha emitters (energy 6 MeV); they have fairly short half-lives, 162.8 days and 18.1 years, and give as much as 120 W/g and 3 W/g of heat, respectively. Therefore, curium can be used in its common oxide form in radioisotope thermoelectric generators like those in spacecraft. This application has been studied for the 244Cm isotope, while 242Cm was abandoned due to its prohibitive price, around 2000 USD/g. 243Cm with a ~30-year half-life and good energy yield of ~1.6 W/g could be a suitable fuel, but it gives significant amounts of harmful gamma and beta rays from radioactive decay products. As an α-emitter, 244Cm needs much less radiation shielding, but it has a high spontaneous fission rate, and thus a lot of neutron and gamma radiation. Compared to a competing thermoelectric generator isotope such as 238Pu, 244Cm emits 500 times more neutrons, and its higher gamma emission requires a shield that is 20 times thicker—2 inches (51 mm) of lead for a 1 kW source, compared to 0.1 inches (2.5 mm) for 238Pu. Therefore, this use of curium is currently considered impractical. A more promising use of 242Cm is for making 238Pu, a better radioisotope for thermoelectric generators such as in heart pacemakers. The alternate routes to 238Pu use the (n,γ) reaction of 237Np, or deuteron bombardment of uranium, though both reactions always produce 236Pu as an undesired by-product since the latter decays to 232U with strong gamma emission.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.